International braz j urol · 2012 · 13 citations · 20 references
MedicinePharmacotherapyUrologyProstate DiseaseUrologic SurgeryVoiding DysfunctionBenign Prostatic HyperplasiaUrinary DysfunctionBenign Prostatic EnlargementMale Lower Urinary Tract SymptomsPlacebo ComparatorsProstatic ObstructionSymptom Score ImprovementTadalafil TherapyUrinary Symptoms Management
OBJECTIVES: To evaluate safety and efficacy of tadalafil on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in patients treated with standard medication. MATERIALS AND METHODS: In this case-controlled randomized clinical trial, from November 2008 to August 2009, 132 patients with obstructive and irritative urinary tract symptoms due to BPH, IPSS ≥ 8, no indication for surgical intervention and that reached plateau levels of response to treatment were selected. These patients were randomly allocated in two groups (each containing 66 patients). The treatment group received standard treatment of BPH and tadalafil (10 mg nightly); the placebo group received only standard treatment of BPH. IPSS, maximum urinary flow rate (Qmax) and quality of life were assessed before and after a 3-month period of study. RESULTS: Before treatment, mean IPSS, Qmax and quality of life values in the treatment and placebo groups were 13.06 ± 4.37 and 13.66 ± 4.25, 8.92 ± 2.96 mL/s and 9.09 ± 2.91 mL/s, 2.93 ± 0.86 and 2.66 ± 0.78, respectively. After treatment, mean IPSS, Qmax, and quality of life values in treatment group were 7.66 ± 3.99, 9.99 ± 4.76 mL/s and 1.80 ± 0.98, respectively. These findings were compared to corresponding values of the placebo group (11.37 ± 3.64, 8.73 ± 2.22 mL/s and 2.19 ± 0.53, respectively): IPSS and quality of life were significantly different but Qmax didn't show a significant change. CONCLUSIONS: Tadalafil improves quality of life and urinary symptoms in patients with LUTS suggestive of BPH, but doesn't have any significant effect on Qmax. Therefore, this drug may be effectively used in combination with standard medical therapies for BPH.
20
Kevin T. McVary, William B. Monnig, Joseph L. Camps et al. · The Journal of Urology · 2007 · 350 citations
Medicine, Pharmacotherapy, Urology +16
Christian G. Stief, Hartmut Porst, D. Neuser et al. · European Urology · 2008 · 278 citations
Medicine, Pharmacotherapy, Urology +12
Sildenafil influences lower urinary tract symptoms
Elena Kulinskaya, Tom McNicholas, G. Boustead et al. · British Journal of Urology · 2002 · 255 citations
Medicine, Pharmacotherapy, Urology +14